Search fresh public links, source activity, and post angles for Amgen.
Fresh curated links around Amgen are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines. The post Amgen pipeline’s next growth cycle: replacing its old block...
On March 31, 2026, the District Court for the District of New Jersey entered a Consent Order and Judgment in the BPCIA litigation Amgen brought against Henlius and Organon concerni...
On March 31, 2026, Amgen reached a settlement with Shanghai Henlius Biotech, resolving BPCIA litigation No. 1:25-cv-12160 (D.N.J.) / 1:25-md-03138 (D.N.J.) concerning Prolia® / Xge...
The fall of Amgen Anonymous (not verified) Sun, 05/17/2026 - 08:33 field_thread_url https://cafepharma.com/boards/threads/the-fall-of-amgen.709419/...
The findings could help Amgen defend Tepezza’s market-leading position against emerging rivals, though some analysts expressed doubt about its competitive standing.
Tavneos’ original developer hid a study analysis and then altered data, the FDA alleged. Elsewhere, Erasca’s RAS drug was met with skepticism and Rocket Pharma sold a voucher.
On April 7, 2026, Biocon announced the U.S. commercial launch of Bosaya™ / Aukelso™ (denosumab-kyqq), biosimilars of Amgen’s Prolia® / Xgeva® (denosumab)....By: Venable L...
Amgen has pulled the plug on midstage drug candidates for cancer and the autoimmune disease Sjögren’s syndrome, terminating five clinical trials in the process.
On March 30, 2026, the FDA approved Teva’s biosimilar Ponlimsi™ (denosumab-adet), referencing Amgen’s Prolia® (denosumab), for all indications of the reference product....By: Venab...
Argenx Anonymous (not verified) Sat, 05/30/2026 - 14:41 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...
Twenty people in Japan died after taking Tavneos, though it's unclear whether the drug killed those people, a media report said.
On March 30, 2026, Teva announced that the FDA and the European Medicines Agency (EMA) accepted regulatory submissions for its proposed biosimilar to Xolair® (omalizumab), TEV-4577...
Denosumab Challenged Claim Types in Litigation: Claims are counted in each litigation, so claims from the same patent challenged in multiple litigations are counted more than once....
Denosumab Challenged Claim Types in Litigation: Claims are counted in each litigation, so claims from the same patent challenged in multiple litigations are counted more than once....
Boehringer Ingelheim and Amgen have both canned early-stage immunology candidates after the prospects showed little clinical promise.
Tocilizumab Challenged Claim Types in IPRs: Claims are counted in each IPR, so claims from the same patent challenged in multiple IPRs are counted more than once. Within each IPR,...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.